Ftse Mib
33.220,31
-0,29%
DAX
18.067,91
-0,31%
S&P 500
5.487,03
0,25%
NASDAQ
17.862,23
0,03%
Bitcoin
65.113,85
0,23%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immutep Limited (PBMD) Immutep Limited (PBMD) Notizie

PBMD

Immutep Limited (PBMD)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PBMD
DataOraFonteTitoloSimboloCompagnia
23/02/201812:09Edgar (US Regulatory)Report of Foreign Issuer (6-k)NASDAQ:PBMDImmutep Limited
28/11/201701:12GlobeNewswire Inc.Prima BioMed Becomes ImmutepNASDAQ:PBMDImmutep Limited
22/11/201700:07GlobeNewswire Inc.Prima Secures European Patent Grant for Lead Product IMP321 in CancerNASDAQ:PBMDImmutep Limited
20/11/201707:59GlobeNewswire Inc.Prima BioMed Changes Its Name to Immutep LtdNASDAQ:PBMDImmutep Limited
15/11/201709:11GlobeNewswire Inc.Eftilagimod Alpha (LAG-3Ig Or IMP321) Pre-IND Meeting With the FDANASDAQ:PBMDImmutep Limited
08/11/201723:45GlobeNewswire Inc.New Eftilagimod Alpha (LAG-3Ig or IMP321) Data for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual...NASDAQ:PBMDImmutep Limited
03/11/201711:01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:PBMDImmutep Limited
01/11/201700:15GlobeNewswire Inc.Dr. Frédéric Triebel Presented at the World Immunotherapy Congress 2017NASDAQ:PBMDImmutep Limited
20/10/201705:23GlobeNewswire Inc.Dr. Frédéric Triebel Presenting at the World Immunotherapy Congress 2017NASDAQ:PBMDImmutep Limited
19/10/201722:41Edgar (US Regulatory)Securities Registration (foreign Private Issuer) (f-3)NASDAQ:PBMDImmutep Limited
19/10/201722:39Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PBMDImmutep Limited
17/10/201706:37GlobeNewswire Inc.IMP321 New Data Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2017 Annual MeetingNASDAQ:PBMDImmutep Limited
08/09/201707:25GlobeNewswire Inc.Prima Secures Japanese Patent Grant for IMP731 AntibodyNASDAQ:PBMDImmutep Limited
05/09/201709:54GlobeNewswire Inc.Prima Secures Japanese Patent Grant for Lead Product IMP321 in Infectious DiseaseNASDAQ:PBMDImmutep Limited
30/08/201712:07GlobeNewswire Inc.Prima BioMed and Monash University Receive Funding Grant for LAG-3 Research ProjectNASDAQ:PBMDImmutep Limited
21/08/201702:07GlobeNewswire Inc.Prima BioMed Appoints Non-Executive Director to the BoardNASDAQ:PBMDImmutep Limited
16/08/201704:01GlobeNewswire Inc.Prima BioMed Receives A $1.3 Million Tax Refund From French GovernmentNASDAQ:PBMDImmutep Limited
18/07/201702:33GlobeNewswire Inc.Financial Update 2H17NASDAQ:PBMDImmutep Limited
17/07/201702:37GlobeNewswire Inc.Prima BioMed Announces Second Milestone Payment for IMP701 ProgramNASDAQ:PBMDImmutep Limited
14/07/201719:45Edgar (US Regulatory)Small Company Offering and Sale of Securities Without Registration (d)NASDAQ:PBMDImmutep Limited
10/07/201705:46GlobeNewswire Inc.Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical TrialNASDAQ:PBMDImmutep Limited
30/06/201723:21Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PBMDImmutep Limited
29/06/201717:39GlobeNewswire Inc.Prima BioMed Announces Pricing of US$5.0 Million Registered Direct Offering of Its American Depositary SharesNASDAQ:PBMDImmutep Limited
28/06/201723:22Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:PBMDImmutep Limited
26/06/201712:33GlobeNewswire Inc.Operational UpdateNASDAQ:PBMDImmutep Limited
05/06/201702:36GlobeNewswire Inc.LAG-3Ig (IMP321) Demonstrates Positive Safety and Efficacy Qualities in Breast Cancer Clinical TrialNASDAQ:PBMDImmutep Limited
01/06/201702:54GlobeNewswire Inc.Prima BioMed Announces Formation of Clinical Advisory BoardNASDAQ:PBMDImmutep Limited
18/05/201702:27GlobeNewswire Inc.Data From Prima BioMed AIPAC Clinical Trial to be Presented at 2017 ASCO ConferenceNASDAQ:PBMDImmutep Limited
19/04/201703:45GlobeNewswire Inc.Prima BioMed Receives Approval for Third Cohort of Phase I Melanoma TrialNASDAQ:PBMDImmutep Limited
12/04/201710:25GlobeNewswire Inc.Prima BioMed Receives A$492,144 Tax Refund From Australian GovernmentNASDAQ:PBMDImmutep Limited
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:PBMD

La tua Cronologia

TSXV
EBCD.P
Eureka Capital
NASDAQI
OMXSPI
OMX Stockholm PI
TG
2UH
Angi
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network